KRAS Program. (i) Unless otherwise agreed to by the Parties or otherwise explicitly set forth in the POC Plan for the KRAS Program, (A) Moderna will be responsible for Manufacturing and supply of mRNA-5671 in accordance with Exhibit K, and (B) Merck shall be responsible for (x) after the KRAS Transition Date, the conduct of the Phase I Clinical Study and Phase II Clinical Study for mRNA-5671, including [***], and (y) supply of Keytruda for use in such Clinical Studies under such POC Plan.
Appears in 2 contracts
Samples: Vaccine Collaboration and License Agreement (Moderna, Inc.), Vaccine Collaboration and License Agreement (Moderna, Inc.)
KRAS Program. (i) Unless otherwise agreed to by the Parties or otherwise explicitly set forth in the POC Plan for the KRAS Program, (A) Moderna will be responsible for Manufacturing and supply of mRNA-5671 in accordance with Exhibit K, and (B) Merck shall be responsible for (x) after the KRAS Transition Date, the conduct of the Phase I Clinical Study and Phase II Clinical Study for mRNA-5671, including [***], and (y) supply of Keytruda for use in such Clinical Studies under such POC Plan.and
Appears in 2 contracts
Samples: Vaccine Collaboration and License Agreement, Vaccine Collaboration and License Agreement
